Clinical trials: Pulmonary Artery Hypertension
Pulmonary Arterial Hypertension
Pilot Study of the Safety and Efficacy of Carvedilol in Pulmonary Arterial Hypertension
The purpose of this study is to determine whether carvedilol treatment of patients with pulmonary arterial hypertension and associated right heart failure is safe and results in an improved function of the right heart.
- Trial name
- NCT00964678
- Testing
- Carvedilol
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Virginia Commonwealth University
Portopulmonary Hypertension
Revatio Portal-Pulmonary Arterial Hypertension Trial
The investigators propose the first prospective, double blind, randomized controlled trial of treatment for pulmonary arterial hypertension (PAH) related to underlying portal hypertension.
- Trial name
- RePo1 (NCT01517854)
- Testing
- Sildenafil
- Where
- 3 sites in Canada
- Volunteers
- 12 people
- Sponsor
- University Health Network, Toronto
Essential Hypertension
Physical Activity, Air Pollution, and High Blood Pressure
The investigators are investigating the effects of traffic-related air pollution (TRAP) on the cardiovascular and pulmonary response to exercise in patients with hypertension using a real world randomized, crossover study design.
- Trial name
- NCT05092672
- Testing
- Exercise
- Where
- Canada
- Volunteers
- 21 people
- Sponsor
- University of British Columbia
Insulin Resistance
Insulin- and Glucose Metabolism in Pulmonary Arterial Hypertension
Insulin resistance is a key mechanism in metabolic disorders, which has also been implicated in the development of pulmonary hypertension.
- Trial name
- NCT03584607
- Where
- Austria
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Medical University of Graz
Idiopathic Pulmonary Arterial Hypertension, Eisenmenger Syndrome
Exercise Capacity and Quality of Life in Patients With PPH Receiving Short Term Oral L-Citrulline Malate
Due to vasodilatory properties of the NO, one of the therapeutic approaches for IPAH is oral use of nitric oxide precursors (10).
- Trial name
- NCT01683981
- Testing
- L-Citrulline Malate
- Where
- Iran
- Volunteers
- 25 people
- Sponsor
- Masih Daneshvari Hospital
Pulmonary Arterial Hypertension
A Study of Pulmonary Arterial Hypertension Participants Treated With Macitentan or Selexipag
The purpose of the study is to evaluate the change from baseline to 12 months after study enrollment in the number of the following non-invasive risk criteria: World Health Organization Functional Class (WHO/FC), 6-minute walk…
- Trial name
- INSPECTIO (NCT04567602)
- Testing
- PAH medication
- Where
- 30 sites in Italy
- Volunteers
- 372 people
- Sponsor
- Janssen-Cilag S.p.A.
Aortic Stenosis, Mitral Regurgitation
Evaluating Infrasonic Hemodynography
This comparative diagnostic accuracy study will determine the accuracy of a noninvasive wearable infrasonic sensor to detect the mechanical, electrical, and hemodynamic function of the cardiovascular system.
- Conditions
- Aortic Stenosis, Mitral Regurgitation, Pulmonary Hypertension, Heart Failure, Systolic
- Trial name
- NCT04636892
- Testing
- MindMics earbud
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Scripps Health
Pulmonary Hypertension, Pain
Qutenza®-Remodulin® in Pulmonary Arterial Hypertension Patients
The investigators hypothesise that pre-application of Qutenza® patches to the skin may reduce pain at the site of Remodulin® SC infusion (sited 1 to 2 weeks later at the site of Qutenza pre-application), in which case it would…
- Trial name
- NCT01393795
- Testing
- Qutenza, Tegaderm
- Where
- United Kingdom
- Volunteers
- 11 people
- Sponsor
- Imperial College London
Pulmonary Arterial Hypertension
Nitric Oxide, GeNO Nitrosyl Delivery System
The primary aim of the study is to evaluate the safety, tolerability and device performance of the GeNO nitrosyl delivery system during RHC.
- Trial name
- NCT01165047
- Testing
- Nitric Oxide
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Wake Forest University Health Sciences
Pulmonary Arterial Hypertension
A Study of Sotatercept in Japanese Pulmonary Arterial Hypertension (PAH) Participants (MK-7962-020)
This local Phase 3 study is planned to confirm the efficacy and safety in Japanese PAH participants. The primary population of this study is Japanese PAH participants with World Health Organization Functional Class (WHO FC) II or…
- Trial name
- NCT05818137
- Testing
- Sotatercept
- Where
- 17 sites in Japan
- Volunteers
- 46 people
- Sponsor
- Merck Sharp & Dohme LLC
Pulmonary Arterial Hypertension, Pulmonary Hypertension
Sitaxsentan Efficacy And Safety Trial With A Randomized Prospective Assessment Of Adding Sildenafil (SR-PAAS)
This protocol is for subjects with pulmonary arterial hypertension and is the first of 3 studies forming the Sitaxsentan efficacy and safety trial with Randomized Prospective Assessment of Adding Sildenafil (SR-PAAS) program.
- Trial name
- NCT00795639
- Testing
- Sitaxsentan
- Where
- 85 sites in United States, Argentina and 22 more
- Volunteers
- 183 people
- Sponsor
- Pfizer
Takayasu Arteritis With Pulmonary Artery Involvement, Pulmonary Arterial Hypertension Associated With Connective Tissue Disease
Clinical Features and Prognosis of Takayasu's Arteritis With Pulmonary Arteries Involvement
The purpose of this study is to identify the clinical features, management pattern and long-term outcomes of patients with pulmonary arteries involvement in Takayasu's arteritis (TAK-PAI).
- Trial name
- CAPTAIN (NCT07184814)
- Where
- China
- Volunteers
- 150 people
- Sponsor
- China-Japan Friendship Hospital
Pulmonary Arterial Hypertension
Beraprost-314d Added-on to Tyvaso® (BEAT)
This is a multicenter, double-blind, randomized, placebo-controlled Phase 3 study, to assess the efficacy and safety of BPS-314d-MR when added-on to inhaled treprostinil (Tyvaso®)in patients with pulmonary arterial hypertension.
- Trial name
- BEAT (NCT01908699)
- Testing
- Beraprost Sodium 314d Modified Release Tablets
- Where
- 75 sites in United States, Israel
- Volunteers
- 273 people
- Sponsor
- Lung Biotechnology PBC
Idiopathic Pulmonary Arterial Hypertension, Cardiomyopathy
Comparison of Inhaled Nitric Oxide and Oxygen in Participants Reactivity During Acute Pulmonary Vasodilator Testing
The primary purpose of this study is to compare the number of participants with reversible pulmonary hypertension (vasoreactivity) due to nitric oxide for inhalation and oxygen as compared to 100% oxygen.
- Trial name
- NCT00626028
- Testing
- Nitric Oxide for inhalation, Oxygen, Nitric Oxide plus Oxygen
- Where
- 18 sites in United States, France and 3 more
- Volunteers
- 136 people
- Sponsor
- Mallinckrodt
Pulmonary Arterial Hypertension
A Study to Assess the Safety, Tolerability, and Hemodynamic Response of PB1046 in Subjects With PAH
PB1046-PT-CL-0005 is an open-label, dose-titration study to assess the safety, tolerability, and hemodynamic effects of individually dose-titrated PB1046 administered by weekly subcutaneous injection for 8 weeks in adult subjects…
- Trial name
- NCT03315507
- Testing
- PB1046 Subcutaneous Injection
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- PhaseBio Pharmaceuticals Inc.
Pulmonary Arterial Hypertension
Effects of Pulmonary Hypertension Therapy in Atypical Pulmonary Arterial Hypertension
The purpose of this study is to characterize the clinical and hemodynamic response of Pulmonary Arterial Hypertension (PAH) therapy in patients with atypical PAH and risk factors for left heart disease.
- Trial name
- NCT04787445
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Mayo Clinic
Hypertension, Pulmonary
An Open Multiple Dose Titration Study In Patients With Pulmonary Hypertension
This is a study to demonstrate the feasibility of an individual dose titration scheme based on the systolic blood pressure with a dose range from 1.0 mg TID to 2.5 mg TID.
- Trial name
- NCT00454558
- Testing
- Riociguat (Adempas, BAY63-2521)
- Where
- 15 sites in Germany
- Volunteers
- 75 people
- Sponsor
- Bayer
Pulmonary Arterial Hypertension
Evaluation of Metformin Activity in Addition to Conventional Treatment of Grade II or III Pulmonary Arterial Hypertension (PAH)
Treatment of PAH includes exercise limitation, non specific agents (anticoagulants, diuretics and supplemental oxygen), pulmonary specific vasodilators and antiproliferative agents.
- Trial name
- MetHTAP (NCT01352026)
- Testing
- Metformin
- Where
- 2 sites in France
- Sponsor
- Nantes University Hospital
Hypertension, Arthritis
The Health Access and Recovery Peer Program
Individuals with serious mental illnesses (SMI) face high rates of medical comorbidity as well as challenges in managing these conditions.
- Conditions
- Hypertension, Arthritis, Coronary Artery Disease, Hepatitis
- Trial name
- HARP (NCT01725815)
- Testing
- HARP Intervention
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- Emory University
Pulmonary Arterial Hypertension
An Open Label Extension Study to Evaluate the Safety of Continued Therapy of Subcutanous Remodulin® in Pulmonary Arterial Hypertension
This is a multicenter, open-label trial to evaluate the safety of continued therapy with subcutaneous Remodulin® in subjects with pulmonary arterial hypertension (PAH) who complete the CVT-CV-003 study.
- Trial name
- NCT02882126
- Testing
- Subcutaneous Treprostinil
- Where
- 10 sites in China
- Sponsor
- United Therapeutics